Abstracts tagged "autoimmune diseases"

Abstract Number: 2191 • ACR Convergence 2022
Long-term Outcomes of Children Born to Mothers with Systemic Lupus Erythematosus: A Nationwide Population-based Study in Korea
In Ah Choi¹, Ji Hyoun Kim², Sung Hae Chang³, Hyun Jung Kim⁴ and Hyeong Sik Ahn⁴, ¹Chungbuk National University, Cheongju, Republic of Korea, ²Chungbuk National University Hospital, Cheongju, Republic of Korea, ³Soonchunhyang University College of Medicine, Bongmyeong-dong, Dongnam-gu, Cheonan-si, Republic of Korea, ⁴Institute for Evidence-based Medicine, Cochrane Korea, Seoul, Republic of Korea
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease that primarily affects women of childbearing age, and epidemiologic studies have shown poor maternal and fetal…
Abstract Number: 0042 • ACR Convergence 2022
The Pathogenic Role of Lymphatic Vessels in Autoimmune Valvular Carditis
Amritha Yellamilli¹, Victoria Osinski², Maria Firulyova³, Jennifer Auger⁴, Lee Meier², Jessica Faragher⁵, Aubyn Marath⁶, Konstantin Zaitsev³ and Bryce Binstadt⁵, ¹Stanford University School of Medicine, Palo Alto, ²University of Minnesota School of Medicine, Minneapolis, MN, ³ITMO University, Saint Petersburg, Russia, ⁴University of Minnesota Medical School, Minneapolis, MN, ⁵University of Minnesota, Minneapolis, MN, ⁶CardioStart, Portland
Background/Purpose: Valvular carditis is a serious complication of systemic autoimmune diseases. Although endothelial cells are thought to play an important role in autoimmune valvular carditis,…
Abstract Number: 0161 • ACR Convergence 2022
Lenabasum, a Cannabinoid Type 2 Receptor Agonist, Exerts Anti-Inflammatory Effects in Dermatomyositis in Th1 Cells
DeAnna Diaz¹, Thomas Vazquez², Nilesh Kodali³, Madison Grinnell⁴, Emily Keyes⁴, Josh Dan⁴, Grant Sprow⁵, Muhammad Bashir⁶, Meena Sharma⁷ and Victoria Werth⁸, ¹Philadelphia College of Medicine, Philadelphia, PA, ²FIU Wertheim College of Medicine, Virginia Beach, VA, ³New Jersey Medical School, Coppell, TX, ⁴Philadelphia VAMC, Philadelphia, PA, USA and Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, ⁵Albert Einstein College of Medicine, Philadelphia, PA, ⁶University of Pennsylvania, Philadelphia, PA, ⁷Philadelphia VAMC, Philadelphia, PA, USA and Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ⁸University of Pennsylvania and Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA
Background/Purpose: Dermatomyositis (DM) is a chronic, systemic autoimmune disease affecting the skin, muscle, and lungs. Lenabasum, a non-psychoactive cannabinoid type 2 receptor (CB2R) agonist, is…
Abstract Number: 0555 • ACR Convergence 2022
Heterogeneity in Origin and Function of Distinct Human Synovial-tissue Dendritic Cells in Health, Active Rheumatoid Arthritis (RA) and RA in Disease Remission
Aziza Elmesmari¹, Lucy MacDonald², Jack Frew², Domenico Somma², Clara Di Mario³, Audrey Paoletti⁴, Diane Vaughan⁵, Barbara Tolusso⁶, Simone Perniola⁶, Marco Gessi⁷, Leandro Lemgruber⁵, Maria Rita Gigante⁸, Luca P Petricca⁹, Laura Bui⁷, Dario Bruno³, charles McSharry⁵, John D Isaacs¹⁰, Iain B McInnes¹¹, Simon Milling⁵, Elisa Gremese³, Thomas D Otto², Kenneth Baker¹², Stefano Alivernini⁶ and Mariola Kurowska-Stolarska¹, ¹Research into Inflammatory Arthritis Centre Versus Arthritis (RACE), University of Glasgow, Glasgow, Scotland, United Kingdom, ²Research into Inflammatory Arthritis Centre Versus Arthritis (RACE), University of Glasgow, Glasgow, Scotland, United Kingdom, ³Immunology Research Core Facility, Gemelli Science and Technology Park, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, ⁴University of Glasgow, Glasgow, Scotland, United Kingdom, ⁵Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, Scotland, United Kingdom, ⁶Immunology Research Core Facility, Gemelli Science and Technology Park, Fondazione Policlinico Universitario A. Gemelli IRCCS,, Rome, Italy, ⁷Institute of Pathology, Fondazione Policlinico Universitario A. Gemelli IRCCS,, Rome, Italy, ⁸Division of Rheumatology, Fondazione Policlinico Universitario A. Gemelli IRCCS,, Rome, United Kingdom, ⁹Division of Rheumatology, Fondazione Policlinico Universitario A. Gemelli IRCCS,, Rome, Italy, ¹⁰Institute for Translational and Clinical Research, Newcastle University and Musculoskeletal Unit, Newcastle upon Tyne Hospitals, Newcastle upon Tyne, United Kingdom, ¹¹Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, Scotland, United Kingdom, ¹²Institute for Translational and Clinical Research, Newcastle University and Musculoskeletal Unit, Newcastle upon Tyne Hospitals, Newcastle, United Kingdom
Background/Purpose: Current treatments for RA do not restore the immune tolerance characteristic of health. Dendritic cells (DC) are one of the cell types that can…
Abstract Number: 0651 • ACR Convergence 2022
Inflammatory Dendritic Cell Drive Intra-renal T Cells to Double-negative T Cell in Lupus Nephritis
Latha Prabha Ganesan, Shane Bruckner, Noushin Saljoughian, James Turman, Murugesan Rajaram, Brad Rovin, Wael Jarjour and Samir Parikh, The Ohio State University, Columbus, OH
Background/Purpose: The pathogenesis of lupus nephritis (LN) is incompletely understood stalling progress and resulting in suboptimal patient outcomes. We previously identified a novel inflammatory dendritic…
Abstract Number: 0741 • ACR Convergence 2022
Prescribing Patterns of SGLT2 Inhibitors for Patients with Autoimmune Rheumatic Disease
Emily G Oakes¹, Jack Ellrodt¹, May Choi², Hongshu Guan¹ and Karen Costenbader¹, ¹Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital | University of Calgary, Calgary, AB, Canada
Background/Purpose: Sodium-glucose co-transporter 2 inhibitors (SGLT2i, dapagliflozin, canagliflozin, and empagliflozin) are a class of oral hypoglycemic medication for management of Type II diabetes mellitus (T2D),…
Abstract Number: 0792 • ACR Convergence 2022
Post-mRNA Vaccine Flares in Autoimmune Inflammatory Rheumatic Diseases: Results from the COronavirus National Vaccine Registry for ImmuNe Diseases SINGapore (CONVIN-SING)
Margaret Ma¹, Amelia Santosa¹, Kok Ooi Kong², Chuanhui Xu², Gim Gee Teng¹, Johnston GX Tang², Anselm Mak³, Frank Tay¹, Victoria WW Ng⁴, Joshua ZE Koh⁴, Warren Fong⁵, Li-Ching Chew⁶, Andrea Low⁷, annie law⁸, Yih Jia Poh⁸, Siaw Ing Yeo⁶, Ying Ying Leung⁹, Wei-Rui Goh⁶, Nur Emilia Roslan¹⁰, Tyng Yu Chuah¹⁰, Stanley Angkodjojo¹¹, Thaschawee Arkachaisri¹², Kai Liang Teh¹³, Kee Fong Phang¹⁴, Melonie Sriranganathan¹⁵, teck Choon Tan¹⁶, Peter Cheung¹ and Manjari Lahiri¹, ¹National University Hospital, Singapore, Singapore, ²Tan Tock Seng Hospital, Singapore, Singapore, ³Division of Rheumatology, Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore, ⁴National University of Singapore, Singapore, Singapore, ⁵Singapore Health Services Pte Ltd (SHS), Singapore, Singapore, ⁶Singapore General Hospital, Singapore, Singapore, ⁷Department of Rheumatology and Immunology, Singapore General Hospital, Singapore, Singapore, ⁸SingHealth, Singapore, Singapore, ⁹Rheumatology Department, Singapore General Hospital, Singapore, Singapore, ¹⁰Sengkang General Hospital, Singapore, Singapore, ¹¹Sengkang General Hospital / Singhealth, Singapore, Singapore, ¹²KK Women's and Children's Hospital, SingHealth, Singapore, Singapore, ¹³KK Women's and Children's Hospital, Singapore, Singapore, ¹⁴Alexandra Hospital, Singapore, Singapore, ¹⁵Changi General Hospital, Singapore, Singapore, ¹⁶Khoo Teck Puat Hospital, Singapore, Singapore
Background/Purpose: Published data suggest no increased rate of flare of autoimmune inflammatory rheumatic diseases (AIIRD) after COVID-19 mRNA vaccination; however, the studies are limited by…
Abstract Number: 0988 • ACR Convergence 2022
Safety, Pharmacokinetics, and Pharmacodynamics of Single Oral Enpatoran Doses in a Phase I Study of Healthy Japanese and Caucasian Participants: Feasibility of Including Asian Participants in a Phase II Study of Enpatoran
Sathej Gopalakrishnan¹, Axel Krebs-Brown², Marco Nogueira Filho¹, Yoshihiro Kuroki³, Angelika Bachmann¹, Andreas Becker¹, Frank Schippers⁴, Markus Fluck¹, Özkan Yalkinoglu¹, Christine Kleinmond⁵, Denesh Chitkara⁶, Cristina Vazquez Mateo⁷, Sanjeev Roy⁸ and Lena Klopp-Schulze¹, ¹Translational Medicine, the healthcare business of Merck KGaA, Darmstadt, Germany, ²Global Biostatistics, the healthcare business of Merck KGaA, Darmstadt, Germany, ³Translational Medicine, Merck Biopharma Co., Ltd., an affiliate of Merck KGaA, Darmstadt, Germany, Tokyo, Japan, ⁴Global Patient Safety, the healthcare business of Merck KGaA, Darmstadt, Germany, ⁵Global Clinical Development, the healthcare business of Merck KGaA, Darmstadt, Germany, ⁶Global Clinical Development, EMD Serono, Billerica, MA, ⁷Global Clinical Development, EMD Serono, an affiliate of Merck KGaA, Darmstadt, Germany, ⁸Global Clinical Development, Ares Trading SA, an affiliate of Merck KGaA, Darmstadt, Germany
Background/Purpose: Enpatoran, a novel, highly selective and potent dual toll-like receptor (TLR) 7 and TLR8 inhibitor, is in development for the treatment of autoimmune disorders…
Abstract Number: 1201 • ACR Convergence 2022
Autoimmune Serologies, Cell-Bound Complement Activation Products, and Autoimmune Rheumatic Disease Symptoms After COVID-19 Infection
Emily G Oakes¹, Jack Ellrodt¹, Roberta Alexander², John Conklin², May Choi³, Hongshu Guan¹, Sara Tedeschi¹, Jeffrey Sparks⁴, Siobhan Case⁵, Tiffany Hsu¹, Daniel Solomon¹, Anna Jonsson¹ and Karen Costenbader¹, ¹Brigham and Women's Hospital, Boston, MA, ²Exagen, Inc., Vista, CA, ³Brigham and Women's Hospital | University of Calgary, Calgary, AB, Canada, ⁴Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁵Brigham and Women's Hospital, Boston Children's Hospital, Boston, MA
Background/Purpose: Onset of autoimmune connective tissue disease (CTD) after COVID-19 infection has been reported and complement activation has been implicated. We examined common autoimmune rheumatic…
Abstract Number: 1371 • ACR Convergence 2022
Juvenile Onset SLE in India-Data from a Multi-institutional Inception (INSPIRE) Cohort of Systemic Lupus Erythematosus
Amita Aggarwal¹, Liza Rajasekhar², Parasar Ghosh³, Ashish J Mathew⁴, Chengappa Kavadichanda⁵, Vineetha Shobha⁶, Ranjan Gupta⁷, Saumya Ranjan Tripathy⁸, Manish Rathi⁹, Avinash Jain¹⁰ and Able Lawrence¹, ¹Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, ²Nizam's Institute of Medical Sciences, Madhapur, India, ³Govt of West Bengal, Kolkata, India, Kolkata, West Bengal, India, ⁴Rigshospitalet, Copenhagen, Denmark, ⁵JIPMER, Pondicherry, Puducherry, India, ⁶St. John’s Medical College Hospital, Bangalore, India, ⁷All India Institute of Medical Sciences, New Delhi, India, ⁸SCB medical college, Cuttack, India, ⁹PGIMER Chandigarh, Chandigarh, India, ¹⁰SMS Medical College, Lucknow, India
Background/Purpose: Most Lupus cohorts across the globe have poor representation of patients from South Asia who are ethnically different. We explored the clinical features and…
Abstract Number: 1669 • ACR Convergence 2022
Comparing the Safety and Effectiveness of Methotrexate, TNF and IL6 Inhibitors for the Treatment of Checkpoint Inhibitor Arthritis
Anne Bass¹, Noha Abdel-Wahab², Pankti Reid³, Jeffrey Sparks⁴, Cassandra Calabrese⁵, Deanna Jannat-Khah, DrPH, MSPH⁶, Diviya Rajesh⁶, Nilasha Ghosh⁶, Komal Mushtaq⁷, Farah Al Haj⁸, Adewunmi Falohun⁹, Lydia Gedmintas¹⁰, Lindsey MacFarlane¹¹, Senada Arabelovic¹¹, Adi Diab², Ami Shah¹², Clifton O. Bingham III¹³, Karmela Kim Chan⁶ and Laura C. Cappelli¹⁴, ¹Hospital for Special Surgery/Weill Cornell Medicine, New York, NY, ²UT MD Anderson Cancer Center, Houston, TX, ³University of Chicago Medical Center, Chicago, IL, ⁴Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁵Cleveland Clinic Foundation, Cleveland Heights, OH, ⁶Hospital for Special Surgery, New York, NY, ⁷Cleveland Clinic, Cleveland, OH, ⁸Sinai Grace Hospital/ Detroit Medical Center, Detroit, MI, ⁹MD Anderson Cancer Center, Houston, TX, ¹⁰Brigham and Women's Hospital, Boston, MA, ¹¹Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ¹²Johns Hopkins Rheumatology, Baltimore, MD, ¹³Johns Hopkins University, Baltimore, MD, ¹⁴Johns Hopkins School of Medicine, Baltimore, MD
Background/Purpose: Immune checkpoint inhibitor associated arthritis (ICI-A) affects ∼4% of ICI-treated cancer patients and often persists. Given its long duration, it is important to identify…
Abstract Number: 1860 • ACR Convergence 2022
Lenabasum, a Cannabinoid Type 2 Receptor Agonist, Activates Diverse Cell-specific Pathways in Whole Blood Leukocytes in Dermatomyositis
Nilesh Kodali¹, Thomas Vazquez², DeAnna Diaz³, Josh Dan⁴, Grant Sprow⁵, Rohan Dhiman⁶, Mariko Ogawa-Momohara⁷, Muhammad Bashir⁶, Meena Sharma⁸ and Victoria Werth⁹, ¹New Jersey Medical School, Coppell, TX, ²FIU Wertheim College of Medicine, Virginia Beach, VA, ³Philadelphia College of Medicine, Philadelphia, PA, ⁴Philadelphia VAMC, Philadelphia, PA, USA and Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, ⁵Albert Einstein College of Medicine, Philadelphia, PA, ⁶University of Pennsylvania, Philadelphia, PA, ⁷Nagoya University Graduate School of Medicine, Nagoya, Japan, ⁸Philadelphia VAMC, Philadelphia, PA, USA and Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ⁹University of Pennsylvania and Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA
Background/Purpose: Dermatomyositis (DM) is a systemic autoimmune disease that affects the skin and muscle. Lenabasum, a cannabinoid type 2 receptor (CB2R) agonist, has been developed…
Abstract Number: 2193 • ACR Convergence 2022
Invasive Fungal Diseases in Patients with Autoimmune Diseases: Prospective Data from a Nationwide French Registry
Simon Galmiche¹, Benjamin Thoreau², Stéphane Bretagne³, Alexandre Alanio³, André Paugam⁴, Valérie Bru⁵, Sophie Cassaing⁶, Jean-Pierre Gangneux⁷, Hélène Guégan⁷, Loïc Favennec⁸, Alida Minoza⁹, Florent Morio¹⁰, Julie Bonhomme¹¹, Guillaume Desoubeaux¹², Odile Eloy¹³, Lilia Hasseine¹⁴, Milène Sasso¹⁵, Laurence Millon¹⁶, Anne-Pauline Bellanger¹⁶, Philippe Poirier¹⁷, Maxime Moniot¹⁷, Taieb Chouaki¹⁸, Antoine Huguenin¹⁹, Frédéric Dalle²⁰, Bernard Bouteille²¹, Muriel Nicolas²², Nicole Desbois-Nogard²³, Marie-Elisabeth Bougnoux²⁴, François Danion²⁵, Vincent Poindron²⁶, Antoine Néel²⁷, Karine Boukris-Sitbon²⁸, Fanny Lanternier²⁹ and Benjamin Terrier³⁰, ¹Institut Pasteur, Paris, France, ²AP-HP, Université Paris Cité, INSERM U1016, CNR UMR 8104, Paris, France, ³Institut Pasteur, Université Paris Cité, Centre National de Référence Mycoses Invasives et Antifongiques, UMR 2000, AP-HP, Paris, France, ⁴Parasitologie – Mycologie, Université Paris Cité, Cochin Hospital, AP-HP, Paris, France, ⁵Institut de parasitologie et de pathologie tropicale, Hôpitaux universitaires de Strasbourg, Université de Strasbourg, Strasbourg, France, ⁶Parasitologie - Mycologie, Université de Toulouse, CHU de Toulouse, Toulouse, France, ⁷Université de Rennes, CHU, INSERM, Irset: Institut de Recherche en Santé, Environnement et Travail, UMR_S 1085, Rennes, France, ⁸French National Cryptosporidiosis Reference Center, Rouen University Hospital, Rouen, France, ⁹Département des agents infectieux, Service de Mycologie-Parasitologie, CHU de Poitiers, Poitiers, France, ¹⁰Parasitologe – Mycologie, CHU de Nantes, Nantes, France, ¹¹Microbiologie, CHU de Caen, Caen, France, ¹²Parasitologie - Mycologie - Médecine tropicale, CHU de Tours, Tours, France, ¹³Microbiologie, Hôpital de Versailles, Le Chesnay, France, ¹⁴Parasitologie – Mycologie, hôpital de l'Archet, CHU Nice, Nice, France, ¹⁵Laboratoire de Parasitologie-Mycologie, CHU Nîmes, Université de Montpellier, CNRS, IRD, MiVEGEC, Nîmes, France, ¹⁶Laboratoire de Parasitologie – Mycologie, CHU Besançon, Besançon, France, ¹⁷Parasitologie – Mycologie, CHU de Clermont-Ferrand, Clermont-Ferrand, France, ¹⁸Mycologie – parasitologie, CHU d’Amiens, Amiens, France, ¹⁹Parasitologie – Mycologie, hôpital Maison-Blanche, CHU de Reims, Reims, France, ²⁰Parasitologie – Mycologie, Plateforme de Biologie Hospitalo-Universitaire Gérard Mack, Dijon, France, ²¹Parasitologie – Mycologie, Centre de Biologie et de Recherche en Santé, CHU Dupuytren, Limoges, France, ²²Mycologie – Parasitologie, CHU de Pointe-à-pitre/Abymes, Pointe-à-Pitre, France, ²³Parasitologie – Mycologie, CHU de la Martinique, Fort-de-France, France, ²⁴Institut Pasteur, Unité Biologie et Pathogénicité Fongiques, Département Mycologie, Laboratoire de Parasitologie – Mycologie, Service de Microbiologie, Necker-Enfants Malades University Hospital, AP-HP, Paris, France, ²⁵Maladies infectieuses et tropicales, Hôpitaux universitaires de Strasbourg, Strasbourg, France, ²⁶Immunologie clinique et médecine interne, Hôpitaux universitaires de Strasbourg, Strasbourg, France, ²⁷CHU de Nantes, Nantes, France, ²⁸Institut Pasteur, Université Paris Cité, CNRS, Mycologie Moléculaire, Centre National de Référence Mycoses Invasives et Antifongiques, UMR 2000, Paris, France, ²⁹Infectious Diseases Unit, Necker-Enfants Malades University Hospital, AP-HP, Institut Pasteur, Université Paris Cité, Centre National de Référence Mycoses Invasives et Antifongiques, CNRS UMR 2000, Paris, France, ³⁰National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, Paris, France
Background/Purpose: Patients with autoimmune diseases (AIDs) display a risk of invasive fungal diseases (IFDs), because of the underlying disease or treatments used. Our objective was…
Abstract Number: 0047 • ACR Convergence 2022
Cenerimod, a Novel Selective S1P1 Receptor Modulator, Prevents or Attenuates Joint Inflammation in Several Preclinical Models of Rheumatoid Arthritis
Thomas Hoyler, Jeremy Scherer, Maxime Bulle, Conrad Wyss, Sylvie Froidevaux and Marianne Martinic, Idorsia Pharmaceuticals Ltd., Allschwil, Switzerland
Background/Purpose: Targeting the sphingosine-1-phosphate (S1P) pathway has become an attractive target for therapeutic intervention in autoimmune diseases due to its selective impact on the migration…
Abstract Number: 0167 • ACR Convergence 2022
Accuracy of Multi-Centric Local Determination of Anti-Synthetase Autoantibodies in Patients with Anti-Synthetase Syndrome and Other Autoimmune Diseases
Giovanni Zanframundo¹, Angela Ceribelli², Sara Faghihi Kashani³, Monica Morosini⁴, Sara Bozzini⁵, Natasa Isailovic⁶, Carlo Selmi⁷, Lorenzo Cavagna⁸ and Rohit Aggarwal⁹, ¹Università di Pavia, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy, Milano, Italy, ²Humanitas Research Hospital, Humanitas University, Rozzano (MI) Italy, Borgo San Giacomo, Italy, ³Stanford University, Stanford, CA, ⁴Fondazione IRCCS Policlinico San Matteo, Pavia, Italy, Pavia, Italy, ⁵Fondazione IRCCS Policlinico San Matteo, Pavia, Italy, Pavia, ⁶IRCCS Humanitas Research Hospital, Rozzano (MI), Italy, Rozzano, Italy, ⁷IRCCS Humanitas Research Hospital, Humanitas University, Rozzano (MI), Italy, Rozzano, Italy, ⁸Università di Pavia, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy, Pavia, Italy, ⁹Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: RNA-immunoprecipitation (RNA-IP) is considered the gold standard method for anti-tRNA synthetase antibodies (ARS-Ab) detection. This technique, however, is not widely available, unlike commercial kits,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].